Effectiveness and safety of PrEP
On this occasion, we are going to address a topic of great relevance in public health: the effectiveness and safety of PrEP (Pre-Exposure Prophylaxis) in the prevention of HIV.
PrEP Effectiveness
Numerous studies have shown that PrEP is a highly effective tool for preventing HIV transmission. When taken properly, PrEP can significantly reduce the risk of infection in people who are in high-risk situations, such as serodiscordant couples (one partner has HIV and the other does not) or people who have sex without a condom.
It is essential to take into account that the effectiveness of PrEP is directly related to adherence to treatment. Taking the medication consistently and following the medical instructions is crucial to obtain the best prevention results.
PrEP Safety
In general, PrEP is a safe strategy that is well tolerated by most people. The antiretroviral drugs used in PrEP have been extensively researched and approved by health authorities for use in HIV prevention.
However, as with any medication, it is important to be informed about the possible side effects and associated risks. Some people may experience mild side effects, such as nausea or headaches, which usually go away over time. Also, PrEP does not protect against other sexually transmitted infections (STIs), so continue to practice safe sex and use condoms to prevent the transmission of other diseases.
Access to PrEP
In Colombia, an important step has been taken in the fight against HIV transmission by mandatorily expanding access to the drug PrEP (pre-exposure prophylaxis) within the Health Benefits Plan, formerly known as the Mandatory Health Plan (POS). This plan represents the set of health care benefits to which all Colombian citizens are entitled.
The inclusion of PrEP as part of the Health Benefits Plan was made through Resolution 2292, approved in December 2021, which updated and established new health services starting in 2022. This decision was based on the previous recommendation made in June of the same year by the Ministry of Health through an HIV Guide, which highlighted the importance of this preventive strategy for people at risk of contracting the virus and who wish to protect themselves.
One of the main implications of this measure is that now the Health Promotion Entities (EPS) will not be able to deny the right of a person at risk of contracting HIV to access preventive treatment against the virus.
Conclusion
PrEP is a highly effective and safe tool to prevent HIV transmission in people at risk. Its proper use and consistent adherence to treatment are essential to obtain the best results. It is important that society continue to promote education about PrEP and that people have access to this preventive strategy to reduce the incidence of HIV and improve the quality of life of those at risk.
If you are considering starting PrEP or have concerns about it, we recommend that you seek medical advice and take advantage of the support of health professionals. At CDI, we are committed to providing the support and care necessary to help you protect yourself and maintain good sexual health.